Malarone

Atovaquone/Proguanil, the active ingredient in Malarone, is an antimalarial presented as a 250 mg atovaquone/100 mg proguanil tablet for oral use. It is indicated for both prophylaxis and treatment of malaria caused by Plasmodium species, particularly in non‑immune individuals traveling to endemic regions.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Malarone is an antimalarial drug used for both prophylaxis and treatment of malaria infections.

Prevention of malaria: provides prophylactic protection for travelers and residents in endemic areas. Treatment of acute uncomplicated malaria caused by Plasmodium falciparum: clears the infection and resolves symptoms in diagnosed patients.

Malarone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the abdomen. - Vomiting: occasional expulsion of stomach contents. - Loss of appetite: reduced desire to eat. - Metallic taste: unusual taste sensation in the mouth.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: marked elevation of liver enzymes or jaundice. - Hypersensitivity reactions: including rash, fever, and anaphylaxis. - Hemolytic anemia: rare breakdown of red blood cells, especially in susceptible individuals.

When prescribing Malarone, consider the following precautions to ensure safe use.

Pregnancy: Category B – use only if the benefit outweighs potential risk. Renal impairment: dose adjustment may be required; monitor kidney function. Hepatic impairment: monitor liver enzymes and function during therapy. Concomitant QT‑prolonging drugs: use with caution due to potential cardiac effects. Adherence: complete the full course to prevent resistance development. Store at below 25°C: keep in the original pack, protect from moisture.

Malarone can interact with other medicines; some interactions require avoidance while others need monitoring.

Major Interactions (Avoid): - Rifampin: significantly reduces plasma concentrations of both components, compromising efficacy. - Cimetidine: may increase atovaquone levels, raising risk of toxicity.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: can decrease atovaquone absorption; separate dosing by at least 2 hours. - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Statins (e.g., simvastatin): potential increased risk of myopathy; observe for muscle symptoms.